This Article Full Text Full Text (PDF) Supplementary Data, Hazra et al Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Hazra, A. Articles by Hunter, D. J. PubMed PubMed Citation Articles by Hazra, A. Articles by Hunter, D. J.

Large-Scale Evaluation of Genetic Variants in Candidate Genes for Colorectal Cancer Risk in the Nurses' Health Study and the Health Professionals' Follow-up Study

¹ Program in Molecular and Genetic Epidemiology, Department of Epidemiology, and ² Department of Nutrition, Harvard School of Public Health; ³ Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; ⁴ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; and ⁵ Division of Cancer Epidemiology and Genetics and ⁶ Core Genotype Facility at the Advanced Technology Centre, National Cancer Institute, Department of Health and Human Services, Bethesda, Maryland

Requests for reprints: Aditi Hazra, Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115. Phone: 617-525-2035; Fax: 617-525-2008. E-mail: ahazra{at}hsph.harvard.edu

Advances in genomics offer new strategies for assessing the association of common genetic variations at multiple loci and risk of many diseases, including colorectal cancer. Low-penetrance alleles of genes in many biological pathways, such as DNA repair, metabolism, inflammation, cell cycle, apoptosis, and Wnt signaling, may influence the risk of nonfamilial colorectal cancer. To identify susceptibility genes for colorectal cancer, we designed a large-scale case-control association study nested within the Nurses' Health Study (190 cases and 190 controls) and the Health Professionals' Follow-up Study (168 cases and 168 controls). We used a custom GoldenGate (Illumina) oligonucleotide pool assay including 1,536 single nucleotide polymorphisms (SNP) selected in candidate genes from cancer-related pathways, which have been sequenced and genotyped in the SNP500Cancer project; 1,412 of the 1,536 (92%) of the SNPs were genotyped successfully within 388 genes. SNPs in high linkage disequilibrium (r² 0.90) with another assayed SNP were excluded from further analyses. As expected by chance (and not significant compared with a corrected Bonferroni P = 0.00004), in the additive model, 11 of 1,253 (0.9%) SNPs had a P_trend < 0.01 and 38 of 1,253 (3.0%) SNPs had a P_trend 0.01 and P_trend < 0.05. Of note, the MGMT Lys¹⁷⁸Arg (rs2308237) SNP, in linkage disequilibrium with the previously reported MGMT Ile¹⁴³Val SNP, had an inverse association with colorectal cancer risk (MGMT Lys¹⁷⁸Arg: odds ratio, 0.52; 95% confidence interval, 0.35-0.78; unadjusted P_trend = 0.0003 for the additive model; gene-based test global P = 0.00003). The SNP500Cancer database and the Illumina GoldenGate Assay allowed us to test a larger number of SNPs than previously possible. We identified several SNPs worthy of investigation in larger studies. (Cancer Epidemiol Biomarkers Prev 2008;17(2):311–9)